DeutschNewstral
Article
Fft.com on 2015-06-29 06:32
Samsung Bioepis eyes Nasdaq listing
Related news
Biogen and Samsung Bioepis launch BYOOVIZ (ranibizumab-nuna)jdsupra.com- Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patentjdsupra.com
- Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigationjdsupra.com
- New BPCIA Litigation: Janssen v. Samsung Bioepis (D.N.J.)jdsupra.com
- Recent Launches - Formycon, bioeq and Boryung, Samsung Bioepisjdsupra.com
- FDA Accepts Review of Samsung Bioepis and Biogen’s Ranibizumab Biosimilarjdsupra.com
- Samsung Bioepis Clinical Trial Updatesjdsupra.com
Samsung Bioepis Seeks New Drug Approvalwsj.com
eToro cancels Nasdaq listing coinjournal.net- Samsung Biologics Completes Full Acquisition of Samsung Bioepisjdsupra.com
- Samsung Bioepis and Merck Announce U.S. Launch of Trastuzumab Biosimilarjdsupra.com
- Samsung Bioepis Presents New Biosimilars Data at EULAR 2016jdsupra.com
- Deal Watch: Samsung Bioepis and Takeda Enter into Partnershipjdsupra.com
- EMA Reviews Samsung Bioepis’ Lucentis Biosimilar For Eye Diseasesjdsupra.com
- Biogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologicsjdsupra.com
- Biosimilar Market Update - Biocon Biologics LTD and Samsung Bioepisjdsupra.com
Interactive Brokers Group to resume Nasdaq listingwestfaironline.com- Recent Updates to Nasdaq Listing Rulesjdsupra.com
- FuelCell Energy regains Nasdaq listing compliancewestfaironline.com
Rexahn Pharmaceuticals moving stock listing to Nasdaqthedailyrecord.com